Showing 1761-1770 of 2526 results for "".
- Inflammasome Therapeutics Announces First Patient Dosed in Geographic Atrophy Clinical Trialhttps://modernod.com/news/inflammasome-therapeutics-announces-first-patient-dosed-in-geographic-atrophy-clinical-trial/2482248/Inflammasome Therapeutics announced the first patient has been dosed in a first-in-class clinical trial for a sustained release implant for geographic atrophy (GA) due to age-related macular degeneration (AMD). The phase 1 trial (ClinicalTrials.gov ID NCT06164587) is sponsored by the Univers
- Aqueous Humor Proteome Database Established by Medical College of Georgiahttps://modernod.com/news/aqueous-humor-proteome-database-established-by-medical-college-of-georgia/2482236/The National Eye Institute (NEI) recently announced a database that will enable researchers to better study causes of vision loss has been established by scientists at the Medical College of Georgia (MCG) at Augusta University in Augusta, Georgia. The Aqueous Humor (AH) Proteome Databas
- False Claims Act Complaint Filed Against Regeneron for Fraudulent Drug Pricing Reportinghttps://modernod.com/news/false-claims-act-complaint-filed-against-regeneron-for-fraudulent-drug-pricing-reporting/2482228/The US Department of Justice (DOJ) has filed a complaint under the False Claims Act (FCA) against Regeneron alleging that the company fraudulently inflated Medicare reimbursement rates for Eylea (aflibercept) by knowingly submitting false average sales price reports to CMS that excluded
- Eversight Center Awards 2024 Eye & Vision Research Grantshttps://modernod.com/news/eversight-center-awards-2024-eye-vision-research-grants/2482211/The Eversight Center for Vision and Eye Banking Research in Cleveland, Ohio, recently announced it has awarded four grants to investigators at Tufts University in Boston, Massachusetts; Wayne State University in Detroit, Michigan; and University of Michigan in Ann Arbor, Michigan, to advance prom
- Glaukos Receives Permanent J-Code for iDose TRhttps://modernod.com/news/glaukos-receives-permanent-j-code-for-idose-tr/2482208/Glaukos announced that CMS has assigned a unique, permanent J-code (J7355) for iDose TR (travoprost intracameral implant) 75 mcg, a p
- Viatris Announces US Launch of Ryzumvi for the Reversal of Mydriasishttps://modernod.com/news/viatris-announces-us-launch-of-ryzumvi-for-the-reversal-of-mydriasis/2482191/Viatris and Ocuphire announced the US commercial launch of Ryzumvi (phentolamine ophthalmic solution) 0.75% for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists (e.g., phenylephrine) or parasympatholytic (e.g., tropicamide) agents in the Uni
- Terry Kim, MD, Joins Alcon as Chief Medical Officer and Head of Global Medical Safetyhttps://modernod.com/news/terry-kim-md-joins-alcon-as-chief-medical-officer-and-head-of-global-medical-safety/2482182/Terry Kim, MD, Professor of Ophthalmology at Duke University Eye Center, will join Alcon in April as Chief Medical Officer (CMO) and Head of Global Medical Safety. Dr. Kim serves as Duke Eye Center’s Chief of the Cornea and External Disease Division, Director of the Refractive Sur
- Iveric Bio Receives Permanent J-code for GA Treatment Izervayhttps://modernod.com/news/iveric-bio-receives-permanent-j-code-for-ga-treatment-izervay/2482181/Iveric Bio, a subsidiary of Astellas, announced that CMS has assigned a unique, permanent Healthcare Common Procedure Coding System (HCPS) J-code for Izervay (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy (GA) secondary to age-related macula
- Cliara Awarded US Patent for Contact Lens Force Measurement Devicehttps://modernod.com/news/cliara-awarded-us-patent-for-contact-lens-force-measurement-device/2482179/Cliara has been granted a United States patent for a device designed to accurately measure the force required to remove gas-permeable contact lenses from the eye, according to a company news release. Cliara LLC is collaborating with BostonSight and LV Prasad Eye Institute
- BlueRock Therapeutics and Foundation Fighting Blindness Partner for IRD Studyhttps://modernod.com/news/bluerock-therapeutics-and-foundation-fighting-blindness-partner-for-ird-study/2482178/BlueRock Therapeutics LP, a clinical stage cell therapy company and subsidiary of Bayer, and Foundation Fighting Blindness announced a collaboration to add a new cohort to the Foundation’s 'Uni-Rare natural history study' of people living with inherited retinal diseases (I